Perceptive reports 5.1% stake in Rhythm Pharmaceuticals
Rhythm Pharmaceuticals amended a Schedule 13G to report beneficial ownership stakes held by Perceptive-affiliated entities and Joseph Edelman.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Filing Summary
Rhythm Pharmaceuticals amended a Schedule 13G to report beneficial ownership stakes held by Perceptive-affiliated entities and Joseph Edelman. The filing lists a combined 3,519,626 shares reported for Perceptive Advisors and shows the ownership percentages based on 68,532,607 shares outstanding as of May 1, 2026. The filing states the Master Fund directly holds 2,373,795 shares plus 416,666 shares issuable on conversion of Series A Convertible Preferred Stock, and Capital Solutions Holdings holds 729,165 shares issuable on conversion. The reported percentages are 5.1% for Perceptive Advisors and Mr. Edelman, 4.1% for the Master Fund, and 1.1% for Capital Solutions Holdings.
Insights
Perceptive-affiliated entities report modest, disclosed stakes in Rhythm based on conversion treatment.
The filing specifies 3,519,626 shared voting and dispositive shares attributable to Perceptive Advisors and 68,532,607 shares outstanding as of May 1, 2026, with conversion of Series A Preferred applied at the stated rate. The numbers are explicit and tied to the issuer's Form 10-Q reference.
Cash‑flow treatment is not addressed; the filing documents beneficial ownership structure and voting/dispositive power. Subsequent filings would show any change in position; timing and transaction intent are not disclosed here.
Ownership is reported as shared power across related entities and a managing member.
The report attributes shared voting and dispositive power to Perceptive Advisors, Perceptive Life Sciences Master Fund, Ltd., Perceptive Capital Solutions Holdings, and Joseph Edelman as managing member. It describes managerial and advisory relationships that explain the shared attribution.
This filing is a disclosure of beneficial ownership and governance linkage; it does not report transactions or changes in control mechanics.
Key Figures
Key Terms
Series A Convertible Preferred Stock financial
Beneficial ownership regulatory
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What stake does Perceptive Advisors report in RHYTM?
What ownership percentage is Joseph Edelman reported to have in RHYTM?
Does this Schedule 13G/A disclose recent purchases or sales?
AI-generated analysis. How Rhea-AI works. Not financial advice.